Votrient (pazopanib) is a small molecule pharmaceutical. Pazopanib was first approved as Votrient on 2009-10-19. It is used to treat renal cell carcinoma and soft tissue neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 2, and vascular endothelial growth factor receptor 3. In addition, it is known to target mast/stem cell growth factor receptor Kit, fibroblast growth factor receptor 1, platelet-derived growth factor receptor beta, and macrophage colony-stimulating factor 1 receptor. Votrient's patent is valid until 2023-10-19 (FDA).
|Indication||renal cell carcinoma, soft tissue neoplasms|
|Drug Class||Angiogenesis inhibitors|